© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
San Francisco--A 3-month delay in definitive treatment of high-risk prostate cancer patients seems to increase the risk of recurrence, according to Judd W. Moul, MD, director of the Center for Prostate Disease Research and professor of surgery,
Related Content:
News